Vir selects Samsung Biologics to produce Covid-19 antibodies

13 April 2020 (Last Updated April 13th, 2020 10:55)

Vir Biotechnology has selected South Korea-based Samsung Biologics for large-scale production of antibodies to potentially treat Covid-19.

Under the terms of the alliance, Samsung Biologics will offer manufacturing services for Vir’s monoclonal antibody (mAb) programme targeting the novel coronavirus, SARS-CoV-2.

Read the full article here